Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis

• Published in: Leukemia & lymphoma Vol. 57; no. 3; pp. 676 - 684
• Main Authors: Migdady, Yazan, Salhab, Mohammed, Dang, Nam H., Markham, Merry J., Olszewski, Adam J.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 03.03.2016
• Subjects: Adult; Aged; Aged, 80 and over; Burkitt lymphoma; conditional survival; diffuse large B-cell lymphoma; epidemiology; Female; Humans; Lymphoma, Non-Hodgkin - diagnosis; Lymphoma, Non-Hodgkin - epidemiology; Lymphoma, Non-Hodgkin - mortality; Male; Middle Aged; Neoplasm Staging; non-Hodgkin lymphoma; Population Surveillance; Prognosis; relative survival; SEER Program; Survivors; Young Adult; relative survival; epidemiology; non-Hodgkin lymphoma; diffuse large B-cell lymphoma; Burkitt lymphoma; conditional survival
• ISSN: 1042-8194; 1029-2403
• DOI: 10.3109/10428194.2015.1102246

We evaluated the association of baseline prognostic factors with conditional net survival among survivors of six subtypes non-Hodgkin lymphoma using the SEER program data from 2000-2012. Among 2-year survivors, further prognosis markedly improved in Burkitt's (BL) and diffuse large B-cell lymphoma (DLBCL), and became the same as for follicular lymphoma (5-year net survival ≥ 85%). Mantle cell lymphoma (MCL) demonstrated the worst prognosis of all studied histologies up to 5 years of survivorship. Age and stage lost prognostic significance in BL within 2 years from diagnosis. Racial disparities in net survival disappeared within 2 years for all subtypes, except in chronic lymphocytic leukemia, where black patients had persistently worse prognosis, and in MCL, where they had unexpectedly better prognosis than other races after 2 years. Many baseline factors may lose their initial prognostic value for lymphoma survivors, which should be considered when counseling patients about their prognosis and long-term surveillance.